Companies that are developing local anesthetic products intended to have a long-acting effect should collect trial data on “clinically meaningful outcomes,” such as reduction in hospitalization, even if such information is not sufficient to serve as the basis for approval, the US Food and Drug Administration said in a new draft guidance.
There is great public health interest in assessing endpoints such as reduction in hospitalization or rehospitalization, emergency department visits, or...